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Abstract There is a need for better predictors for short
survival in patients with brain metastases undergoing open
surgery. The graded prognostic assessment (GPA) has
recently been developed to predict survival in patients with
brain metastases. We explored the prognostic capabilities
of GPA in a consecutive neurosurgical population of brain
metastases. Secondarily, we evaluated if GPA scores can
provide information on safety of the operation and post-
operative functional outcome. We retrospectively included
all adult (C18 years) patients undergoing open surgery for
brain metastases from 2004 through 2009 (n = 141). The
population was grouped into GPA 0–1 (n = 22, 16%),
GPA 1.5–2.5 (n = 90, 64%), GPA 3 (n = 19, 14%), and
GPA 3.5–4 (n = 10, 7%) according to the prognostic
indices. Median survival times were 6.3 months (range
0.8–23.7) in GPA 0–1, 7.8 months in GPA 1.5–2.5 (range
0.2–75.0), 14.0 months in GPA 3 (range 0.0–77.4), and
18.4 months in GPA 3.5–4 (range 0.1–63.7). This repre-
sents a signiﬁcant difference between groups (P = 0.010).
There were no associations between GPA and 30-day
mortality (P = 0.871), 3-month mortality (P = 0.750),
complications (P = 0.330) or change in Karnofsky Per-
formance status postoperatively (P = 0.558). GPA scores
hold prognostic properties in patients operated for brain
metastases. However, GPA did not predict short-term
mortality, limiting the clinical usefulness in a neurosurgical
population. The prognostic indices cannot be used alone to
decide if surgery is warranted on an individual basis, or to
evaluate risks and beneﬁts of surgery.
Keywords Brain metastases  Craniotomy  Graded
prognostic assessment  Survival rate  Treatment outcome
Introduction
The brain can be a sanctuary for metastatic cancer disease
as many anti-cancer drugs are unable to cross an intact
blood–brain barrier allowing tumors to grow even when
extracranial disease is effectively treated with chemother-
apy. Most authors believe metastatic brain involvement is a
growing problem, although the true incidence is unknown
[1]. The estimates available are probably underestimates as
registries are often incomplete, neuroimaging is withheld in
asymptomatic patients, and autopsy studies are outdated
[1]. Moreover, there are limitations of even contemporary
brain imaging technologies [2–4].
Treatment options for patients with brain metastases
range from open brain surgery, stereotactic radiosurgery
(SRS), whole brain radiotherapy (WBRT), or mere sup-
portive care with corticosteroids, or combinations. The aim
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control throughout the course of the cancer disease. The
median survival in patients diagnosed with brain metas-
tases is only 4 months, although the variation between
patients is considerable [5]. It is therefore crucial to select
the appropriate therapy to the right patients. Unwarranted
treatment may waste valuable and already limited time for
these patients and can cause serious side effects. Inef-
fective and excessive treatment should also be avoided as
aggressive therapy for brain metastases is associated with
signiﬁcant costs [6, 7]. The choice of treatment often
depends on the clinical condition of the patient, number
of metastatic lesions, depth and eloquence of lesions,
mass effect of lesions, and tumor size [8–10]. Hence,
neurosurgeons usually meet a highly selected patient
population.
Several risk stratiﬁcation scores have therefore been
suggested to aid prognostication and to guide treatment
strategies [11–14]. Attempts to identify short survival (B2
and B3 months) using various indices alone or in combi-
nation have nevertheless been disappointing [15, 16]. The
graded prognostic assessment (GPA) has recently been
developed to predict survival in cancer patients with brain
metastases [14, 17] and its use has been supported [18].
GPA is based on objective and measureable parameters. It
has also been validated outside randomized clinical trials
[19, 20].
To our knowledge, there are two studies validating GPA
in surgically treated patients [20, 21]. One study included
patients who underwent both surgery and WBRT, exclud-
ing all perioperative deaths or serious surgical morbidity
that could warrant only supportive care without WBRT.
This inclusion criterion likely limits external validity. Also,
patients that had undergone prior WBRT (which is, for
example, standard therapy for all small cell lung carcino-
mas) or receiving other adjuvant treatment than WBRT
were not included. This could limit extrapolation of results
to an unselected everyday neurosurgical population. The
other study included only patients with single brain
metastases, likely excluding patients with the worst prog-
noses. In both studies, patients with reoperations seem to
be excluded or at least not accounted for.
In the present study, we aimed to explore the prognostic
capabilities of the GPA in an unselected, consecutive,
neurosurgical population of brain metastases. Although the
GPA instrument was developed to predict patients’ sur-
vival, it was also of interest to evaluate whether GPA
scores can provide information on safety of the operation
and postoperative functional outcome. Further, we sought
in an exploratory fashion for potential surgery-related
parameters such as depth and size of lesion that may pos-
sess independent predictive value in patients with brain
metastases.
Materials and methods
Methods
We retrospectively included all adult (C18 years) patients
operated for brain metastases at the Department of Neu-
rosurgery, St. Olav University Hospital, in the 6-year per-
iod from January 2004 through December 2009. Patients
were followed until death or to 31 December 2010. No
patients were lost to follow-up. Data collection was based
on review of patient hospital ﬁles and image data. We
sought to assess postoperative Karnofsky performance
status (KPS) based on available records approximately
4 weeks after surgery to allow some time for recovery from
transient surgically acquired deﬁcits. We included all
adverse events and serious adverse events in relation to the
surgical procedure, without attempts to deﬁne causality.
This is in coherence with Good Clinical Practice Guide-
lines (http://www.ema.europa.eu: Clinical Safety Data
Management: Deﬁnitions and Standards for Expedited
Reporting). Serious adverse events are deﬁned as any
unexpected medical occurrence (at any dose) in the oper-
ative period, which resulted in death, was life-threatening,
required inpatient hospitalization or prolongation of exist-
ing hospitalization, or resulted in persistent or signiﬁcant
disability/incapacity. Tumor volumes were determined
from preoperative volumes using an ellipsoid model
(4p 9 r
3/3), as described by others [22]. Early postopera-
tive contrast enhanced MRI (\48 h) was used to determine
resection grades. Gross total resection (GTR) was deﬁned
as no visible residual tumor, as opposed to subtotal resec-
tions (STR).
Study population
A total of 141 surgically treated cases with brain metas-
tases were identiﬁed in the study period. Baseline charac-
teristics are presented in Table 1. The mean age was
60.5 years (95% CI, 58.7–62.2) and 70 (50%) of the
patients were female. The median number of brain
metastases was 1 (range 1–11) and 101 (72%) patients
presented with a single brain metastasis. Mean preoperative
KPS was 75 (95% CI, 73–77). Eighty-two (58%) had
metastatic disease outside the brain. Mean maximal depth
of lesion, as measured from the meninges in the craniot-
omy was 35 (95% CI, 33–37) mm. Median preoperative
volume was 9.610 (range 0.24–83.92) ml.
There were 111 (79%) primary operations and 30 (21%)
reoperations. The patients underwent different adjuvant
treatments after the discovery of brain metastases. Twelve
(9%) patients received SRS during follow-up while another
12 patients had undergone SRS for brain metastases prior
to open surgery. In Norway, SRS is centralized to another
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123hospital and patients treated with SRS instead of open
surgery are therefore not included in this study. Sixty
(43%) patients received chemotherapy during follow-up.
Seventy-two (51%) patients received WBRT during fol-
low-up while 24 (17%) patients had undergone WBRT
prior to surgery. In 23 (16%), open surgery was the only
anti-cancer treatment given. In 109 (77%) operations, GTR
was achieved. Diagnostic biopsies only were performed in
2 (1%) cases.
Graded prognostic assessment
GPA has recently been developed to predict survival in
cancer patients with brain metastases [14, 17]. Four clinical
parameters are evaluated with three possible values (0, 0.5
or 1). The parameters include: age (C60, 50–59,
\50 years), KPS (\70, 70–80, 90–100), number of brain
metastases ([3, 2–3, 1), and extracranial metastases
(present, not applicable, none). The score divides patients
into four different prognostic groups (0–1; 1.5–2.5; 3;
3.5–4). Total scores range between 0 and 4 with higher
scores indicating better prognosis.
Three-month-mortality
We sought to explore if GPA score or other possible
prognostic factors could help to identify patients who had
limited survival after surgery. From a surgical and general
point of view, a 3-month expected survival could repre-
sent gross cut-off between worthwhile and futile
treatment.
Statistics
All analyses were done with SPSS, v.16.0 (Chicago, IL,
USA). Statistical signiﬁcance level was set to P B 0.05.
All tests are two-sided. Q–Q plots were used to test for
normal distribution of data. Central tendencies are pre-
sented as medians (range) when data is skewed and for
survival as 18 (12.8%) cases are censored. The tests
applied for analyzing data was chosen as follows. When
both dependent and independent variables were categori-
cal, we have used Pearson’s Chi-square test. Comparisons
of groups with linear data were analyzed with Kruskal–
Wallis test if there were several subgroups. When analyz-
ing changes in KPS (before and after surgery) we used
paired samples t test. Test properties (sensitivity/speciﬁc-
ity) and diagnostic properties (predictive values) were
calculated from 2 9 2 tables. Differences in survival were
analyzed with log-rank test (Mantel Cox) and survival is
presented as Kaplan–Meier plots.
Ethics and approvals
The study was approved by the Regional Ethical Com-
mittee for Health Region Mid-Norway.
Results
Graded prognostic assessment
The population was grouped into GPA 0–1 (n = 22, 16%),
GPA 1.5–2.5 (n = 90, 64%), GPA 3 (n = 19, 14%), and
GPA 3.5–4 (n = 10, 7%) according to the prognostic
indices.
Overall survival
Median survival time (MST) for the entire population was
7.7 months (range 0.0–78.6). MST in the different prog-
nostic groups is presented in Fig. 1 and Table 2. MST were
6.3 months (range 0.8–23.7) in GPA 0–1, 7.8 months
Table 1 Baseline characteristics
Overall (n = 141)
Male (%) 71 (50)
Age, mean (95% CI) 60.5 (58.7–62.2)
C60 (%) 82 (58)
50–59 (%) 38 (27)
\50 (%) 21 (15)
Preoperative KPS, mean (95% CI) 75 (73–78)
KPS 90–100 (%) 40 (28)
KPS 70–80 (%) 76 (54)
KPS\70 (%) 25 (18)
No. of intracranial metastasis, median (range) 1 (1–11)
1 (%) 101 (72)
2–3 (%) 31 (22)
[3 (%) 9 (6)
Intracranial localization (%)
Supratentorial 108 (76.6)
Infratentorial 27 (19.1)
Infra- and supratentorial 6 (4.3)
Known extracranial metastasis (%) 82 (58)
GPA score, median (range) 2 (0–4)
0–1 (%) 22 (16)
1.5–2.5 (%) 90 (64)
3 (%) 19 (13)
3.5–4 (%) 10 (7)
1st neurosurgical operation (%) 111 (79)
Median preoperative volume (range) (ml) 9.610 (0.24–83.92)
Mean depth of lesion (95% CI) (mm) 35 (33–37)
KPS Karnofsky performance status, CI conﬁdence interval, GPA
graded prognostic assessment
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123(range 0.2–75.0) in GPA 1.5–2.5, 14.0 months (range
0.0–77.4) in GPA 3, and 18.4 months in GPA 3.5–4 (range
0.1–63.7). This represents an overall signiﬁcant difference
between groups (P = 0.010).
3-month mortality
Twenty-four patients (17%) died within 3 months after
surgery. There was no signiﬁcant association between GPA
group and 3-month mortality (P = 0.750). Five (23%)
patients were dead in the worst prognostic group compared
to two (20%) patients in the best prognostic group
(Table 2).
Perioperative (30 day) mortality
The perioperative mortality was 7% (n = 10). There was
no signiﬁcant association between perioperative mortality
and the GPA group (P = 0.871). One patient (5%) was
dead in the worst prognostic group compared to 1 (10%) in
the best group (Table 2).
Adverse events and change in Karnofsky performance
status
Adverse events are presented in Tables 2 and 3. In total, we
registered adverse events in 25 (18%) of the operations.
Fig. 1 Kaplan–Meier plots for
overall survival between the
different GPA groups.
a Kaplan–Meier plot for overall
survival (n = 141), a signiﬁcant
difference in overall survival
between groups (P = 0.010).
Censored cases were still alive
at end of follow-up. b Kaplan-
Meier plot for overall survival
in re-operated patients. There
was only one patient in the best
group and as a result of that we
merged the two best groups. Not
signiﬁcant (P = 0.062),
probably due to lack of power.
Censored cases were still alive
at end of follow-up
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There were no signiﬁcant differences between the prog-
nostic groups (P = 0.330). KPS ranged from 10 to 100
preoperatively and from 0 to 100 postoperatively. Mean
preoperative KPS was 75 (95% CI, 73–78), and postoper-
ative KPS was 70 (95% CI, 66–74). This represents a
signiﬁcant reduction in functional performance
(P = 0.005) assessed approximately 4 weeks after the
operation. There were 43 (31%) cases suffering a reduction
in KPS, while 63 (45%) experienced no change, and 35
(25%) improved postoperatively. There was no statistical
association between GPA groups and change in KPS after
surgery (P = 0.558).
Repeated surgery for brain metastasis
Patients undergoing their ﬁrst brain metastases surgery had
MST of 6.7 months (range 0.0–75.0). In our study popu-
lation, 30 (21%) cases had previously been treated with
surgery for brain metastases. This subgroup had MST of
17.2 months (range 1.3–77.4). Each case was grouped into
GPA 0–1 (n = 4, 13%), GPA 1.5–2.5 (n = 19, 63%), GPA
3( n = 6, 20%), and GPA 3.5–4 (n = 1, 3%) according to
the prognostic index. As there was only one patient in the
best prognostic group, we merged the two best groups in
the survival analysis. Survival plot is presented in Fig. 1.I n
cases with repeated surgery, there was no overall signiﬁ-
cant (P = 0.062) difference between groups, probably due
to lack of statistical power. Re-operated patients did not
have signiﬁcantly different GPA scores compared to ﬁrst-
time operations (P = 0.989).
Prediction of 3-month mortality: Exploratory analyses
We explored the test properties and diagnostic properties of
preoperative variables; maximal tumor depth, tumor vol-
ume, tumor location (infratentorial vs supratentorial),
different cut-offs for GPA, age C60 years, number of
metastases and preoperative KPS. The following postop-
erative variables were also explored: resection grades
(GTR vs. STR), new deﬁcits, and adverse events. Results
are presented in Table 4. Depth C40 mm (P = 0.029) and
adverse events (P = 0.001) were signiﬁcantly associated
with 3-month mortality. No clinical useful predictor for
3-month mortality was found. Sensitivity for detecting
3-month mortality were highest with 63% in GPA 0–2,
extracranial metastases and KPS B70 preoperatively. The
highest positive predictive values were found in patients
who experienced new deﬁcits or adverse events postoper-
atively with 29 and 40%, respectively.
Discussion
Prognostication in patients with brain metastases is chal-
lenging, often making it difﬁcult to refrain from aggressive
treatment. Various treatment options may be associated
with important differences in both side effects and effects
within the time frame important for the individual patient.
Thus, caregivers for patients with brain metastasis need a
reliable prognostic marker for deciding how to treat the
individual patient. From a surgical point of view, it would
be of interest to identify patients with short survival
accurately, avoiding over- and under-treatment as pointed
out by Nieder et al. [21, 23].
In the present study we have demonstrated possible use
and limitations of GPA in a consecutive neurosurgical
series of brain metastases. It is our belief that if expected
survival is short (e.g., less than 3 months), open surgery
should preferably be avoided in most patients as other
treatment options may provide symptomatic relief with less
risks and costs in the following weeks, possibly without the
need for hospitalization. Perhaps to no surprise, GPA did
not predict perioperative mortality nor mortality within
Table 2 Clinical outcomes and
associations with GPA score
KPS Karnofsky performance
status, CI conﬁdence interval,
GPA graded prognostic
assessment
a Pearson Chi-square test
b Log rank test
c Kruskal–Wallis test
(comparison between several
groups with non-parametric
linear data)
Outcome
characteristics
Adverse
events (%)
30-day
mortality (%)
3-month
mortality (%)
Median overall
survival; months
(range)
Mean change in
KPS score (95% CI)
Overall
(n = 141, 100%)
25 (18) 10 (7) 24 (17) 7.7 (0.0–77.4) -5( -9t o-2)
GPA 0–1
(n = 22, 15.6%)
6 (27) 1 (5) 5 (23) 6.3 (0.8–23.7) -4( -15 to 7)
GPA 1.5–2.5
(n = 90, 63.8%)
16 (18) 6 (7) 13 (14) 7.8 (0.2–75.0) -4( -7t o0 )
GPA 3
(n = 19, 13.5%)
1 (5) 2 (11) 4 (21) 14.0 (0.0–77.4) -8( -21 to 4)
GPA 3.5–4
(n = 10, 7.1%)
2 (20) 1 (10) 2 (20) 18.4 (0.1–63.7) -14 (-35 to 7)
P-value 0.330
a 0.871
a 0.750
a 0.010
b 0.558
c
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1233 months. This ﬁnding is consistent with earlier attempts to
predict unfavorable outcome with scoring systems (using
B2 and B3 months survival as cutoff) in patients treated
with WBRT [15, 16, 23, 24]. According to our ﬁndings,
GPA is not robust enough to aid selection of treatment
strategies for individual patients in a neurosurgical setting.
We are less convinced of the capabilities of GPA than
Sperduto who claims: ‘‘GPA indices provide the clinician
with an easy and valuable tool to distinguish which patient
warrants aggressive therapy and which patient would be
better served by hospice’’ [7].
Overall survival and surgical mortality
GPA split the patients into four different prognostic groups
as demonstrated in our study. This has previously been
demonstrated in several trials with various treatments [14,
17, 19, 25]. Although GPA seems like a fairly reliable tool
to predict longer term survival in patients with brain
metastases regardless of pattern of care, the frequent out-
liers and the inability to predict short-term survival limit
the clinical usefulness in the individual patient.
Perioperative mortality was 7% in our series which is
comparable to other studies in an unselected neurosurgical
population [26]. Our ﬁndings suggest that GPA is not
suitable for predicting surgical mortality.
Adverse events and change in Karnofsky performance
status
The surgical treatment was associated with signiﬁcant risk
with almost 20% experiencing some kind of adverse event.
This is somewhat more frequent than reported previously,
although different methods for registration make direct
comparisons difﬁcult [26]. We evaluated the postoperative
KPS score rather early (*4 weeks) in an attempt to min-
imize effects of disease progression locally or systemically,
chemotherapy or radiation therapy. If patients with
expected short survival achieve early improvement in
quality of life (QoL) after surgery it may be worth the risk
and cost of surgical treatment. However, according to our
results, the average patient does not improve after surgery
as measured with KPS. However, the physical performance
may improve or maintain stable longer with longer follow-
up as a result of improved local control in the central
nervous system. In the famous randomized study from
Patchell et al., patients treated with surgery and WBRT
were functionally independent longer than the group
receiving WBRT alone [27]. The present study was not
designed to answer how surgery affects QoL compared to
other treatment options, but rather if changes in functional
status could be predicted by GPA. According to our results,
GPA does not give additional prognostic information
concerning postoperative physical performance level.
Repeated surgery for brain metastases
There is no consensus on how to treat recurrent brain
metastases. However, several studies demonstrate
improved functional outcome and survival in patients
treated with repeated surgery [26, 28]. The selection pro-
cess for repeated surgery is probably more restrictive than
for the initial surgery. This is probably why this group had
a MST approximately 10 months longer than the pooled
population in our study. Interestingly, the GPA scores were
similar between those with initial surgery and reoperations.
Thus, although they may be subjects to stricter selection,
this was not reﬂected in the score. Differences in tumor
biology might explain why some patients with a more
Table 3 Adverse events occurring in relation to surgery
Adverse
events no.
(%)
Serious adverse
events
a no. (%)
Epidural/cavity hematoma 1 (0.7%) 1 (0.7)
DVT/PE 3 (2.1) 2 (1.4)
Wound infection 1 (0.7) –
Systemic infection (UTI/
pneumonia)
2 (1.4) 1 (0.7)
Herniation due to edema – 1 (0.7)
Cerebral infarction 3 (2.1) 1 (0.7)
CSF leakage 1 (0.7) 1 (0.7)
Atrial ﬁbrillation 2 (1.4) –
Hydrocephalus – 1 (0.7)
Hyponatremia with generalized
edema
– 1 (0.7)
Peptic ulcer – 1 (0.7)
Delirium 1 (0.7) –
ARDS – 1 (0.7)
Total 14 (9.9) 11 (7.8)
Overall 25 (17.7)
Re-operations due to
complications
4 (2.8)
Additional perioperative deaths
without any known speciﬁc
complication
4 (2.8)
DVT/PE Deep vein thrombosis or pulmonary embolism, UTI urinary
tract infection, ARDS, acute respiratory distress syndrome
a Serious adverse events is here deﬁned as an effect resulting in
death, is life-threatening (refers to an event in which the patient was at
risk of death at the time of the event; it does not refer to an event
which hypothetically might have caused death if it were more severe),
requires inpatient hospitalization or prolongation of existing hospi-
talization or results in persistent or signiﬁcant disability/incapacity.
This is similar to Good Clinical Practice Guidelines for medical trials
(http://www.ema.europa.eu: Clinical Safety Data Management: Def-
initions and Standards for Expedited Reporting)
578 J Neurooncol (2011) 105:573–581
123indolent disease course live long enough to experience
recurrent CNS metastases while being in good enough
condition for repeated surgery. As the number of re-oper-
ated patients is low (n = 30) in our study, the statistical
power is weak (risk of type II error), but we still detected a
near signiﬁcant difference and divergent survival plots
(data is shown) between GPA groups. Thus, it seems likely
that GPA scores are also predictive for survival in patients
operated for recurrent brain metastases.
Exploratory analyses in prediction of 3-month mortality
Due to an apparent need for better predictors for short
survival in a population undergoing open surgery for brain
metastases, we found it natural to search among traditional
surgical parameters, as GPA scores failed to predict short-
term survival. The postoperative predictors cannot be used
in selection of patients, but they may inﬂuence surgical
strategy. The results are from data-driven post-hoc analyses
where we have chosen the most appropriate cut-offs for
prediction of 3-month mortality, and therefore these results
should be interpreted with caution. Table 4 demonstrates
the clinical capabilities and limitations of the different
clinical characteristics. Of the preoperative parameters, we
identiﬁed that depth of lesion predicted early mortality
better than the GPA. A cut-off at 40 mm maximal depth
has 50% sensitivity and this cut-off was signiﬁcantly
associated with 3-month mortality. Thus, depth proved
better than GPA in predicting 3-month mortality. Depth
may be related to the surgical trauma, and deep-seated
lesions may perhaps be more safely treated with SRS. The
clinical usefulness, however, is very limited with a positive
predictive value of only 27%. A recent study among
glioma patients demonstrated shorter survival in patients
with acquired aphasia and motor deﬁcits [29]. This ﬁnding
could also be of interest in other patients with intracranial
tumors. Avoiding complications and new deﬁcits in these
patients with advanced disease is critical for several rea-
sons. First, as indicated by the results in Table 4,i ti s
probably associated with shorter survival. Second, new
deﬁcits are certainly related to impaired QoL [30]. Third,
most complications prolong hospitalization, require treat-
ment and thereby restrict the lives of patients with very
limited time left. Lastly, readmissions and longer hospi-
talization due to treatment-related complications adds to
already inﬂated health budgets [31].
Study limitations
The external validity of our ﬁndings will naturally depend
much on the patient population elsewhere, since referral
traditions and treatment strategies in patients with brain
metastases may vary between institutions. As pointed out
in a recent review, one small RCT and three retrospective
cohort studies have evaluated surgical resection alone
compared to surgery plus post-operative WBRT for the
initial management of a single brain metastasis [9]. Fewer
patients who received post-operative WBRT experienced a
recurrence in the brain compared to those who had surgical
resection alone, but convincing results are lacking con-
cerning overall mortality. As for the present, there is
insufﬁcient evidence to make treatment recommendations
for patients with poor performance scores, advanced sys-
temic disease, or multiple brain metastases [9]. The neu-
rocognitive tolls or potential beneﬁts of WBRT have not so
far been much explored in this setting. In our study
Table 4 Usefulness of different characteristics in predicting 3-month mortality
Clinical characteristics Sensitivity (%) Speciﬁcity (%) Positive predictive value (%) Negative predictive value (%) P value
b
Extracranial metastases 63 43 18 85 0.636
Age C 60 years 58 43 17 83 0.579
GPA 0–1 21 85 23 84 0.438
GPA 0–2 63 42 18 84 0.691
Depth C 40 mm 50 73 27 88 0.029
Volume
a[15 cm
3 38 66 18 84 0.756
Infratentorial 28 77 18 83 0.839
C2 brain metastases 25 71 18 82 0.688
Preoperative KPS B70 63 55 22 88 0.124
Subtotal resection 29 79 22 84 0.493
Adverse events 42 88 40 88 0.001
Acquired deﬁcits 17 91 29 84 0.226
KPS Karnofsky Performance status, GPA graded prognostic assessment
a 15 cm
3 was chosen as cut-off as 3 9 3 9 3 cm approximates 15 cm
3. These diameters are often regarded cut-off for SRS
b Pearson Chi-square test, signiﬁcant values in italics
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123population, WBRT was withheld in a few patients with
expected longer term survival, due to excellent and long-
term control of the extracranial disease. In some patients
with expected poor prognoses, such as patients with KPS
\70 (including perioperative deaths) or poor control of
extracranial disease, WBRT was also not given, as the
main concern was not local recurrence. This among other
local treatment and selection strategies may have inﬂu-
enced results. However, we still believe the external
validity of the results is high for institutions offering open
surgical treatment for brain metastases. There are also
potential biases associated with retrospective evaluation of
own data. The data-driven post-hoc analyses carried out in
the search for potential clinically useful predictors clearly
have a possibility for false positive ﬁndings.
Conclusion
GPA scores holds prognostic properties in a population of
patients operated for brain metastases. However, GPA did
not predict short-term mortality, limiting the clinical use-
fulness in a neurosurgical population. There was no asso-
ciation between GPA and complications or change in
physical performance postoperatively. The prognostic
indices cannot be used alone to decide if surgery is war-
ranted on an individual basis, or to evaluate risks and
beneﬁts of surgery.
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